Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics Inc

0.7880
-0.0185-2.29%
Post-market: 0.80500.0170+2.16%19:45 EDT
Volume:101.78K
Turnover:78.52K
Market Cap:4.28M
PE:-0.05
High:0.8200
Open:0.8000
Low:0.7152
Close:0.8065
Loading ...

Buy Rating for Dermata Therapeutics: Promising Phase 3 Results and Strategic Advantages

TIPRANKS
·
29 Mar

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire
·
28 Mar

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results

Benzinga
·
28 Mar

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Dow Jones
·
27 Mar

Dermata Therapeutics Shares up 68% as Acne Treatment Succeeds Late-Stage Study

THOMSON REUTERS
·
27 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, New Fortress Energy, Northrop Grumman

Reuters
·
27 Mar

BUZZ-Dermata Therapeutics rises after positive late-stage study data of acne treatment

Reuters
·
27 Mar

BRIEF-Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Reuters
·
27 Mar

Dermata Therapeutics Inc - to Initiate Second Phase 3 Trial for Xyngari in H2 2025

THOMSON REUTERS
·
27 Mar

Dermata Therapeutics Inc: Xyngari™ Achieved Its Primary Endpoints

THOMSON REUTERS
·
27 Mar

Dermata Therapeutics Inc - Announces Positive Phase 3 Results for Xyngari in Acne Treatment

THOMSON REUTERS
·
27 Mar

Breaking: Dermata's Xyngari™ Phase 3 Trial Topline Data Meets All Primary Endpoints

THOMSON REUTERS
·
27 Mar

Dermata Therapeutics Shares Halted for News Pending Premarket

THOMSON REUTERS
·
27 Mar

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

ACCESS Newswire
·
18 Mar

BRIEF-Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne

Reuters
·
04 Mar

Dermata Therapeutics announces last patient visit in Phase 3 acne trial

TIPRANKS
·
04 Mar

Dermata Therapeutics Inc - Topline Data Expected by End of March 2025

THOMSON REUTERS
·
04 Mar

Dermata Announces That Last Patient Completes Last Visit in Pivotal Xyngari™ Phase 3 Star-1 Clinical Trial for Acne

THOMSON REUTERS
·
04 Mar

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

PR Newswire
·
04 Mar

APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis

TIPRANKS
·
25 Feb